Description

Flixotid Evochaler (Fluticasone) Aerosolum 125 mcg. 120 doses

Composition

Active ingredient: Fluticasone propionate. Other ingredients: lactose monohydrate, norflurane (HFA 134a).

Mechanism of Action

Pharmacological properties: Fluticasone, a synthetic corticosteroid, exhibits potent anti-inflammatory effects. It acts by reducing airway inflammation, thereby facilitating improved respiratory function. This mechanism aids in managing asthma symptoms and enhancing lung function.

Indications for Use

Indicated for: Flixotid Evochaler is primarily indicated for the maintenance treatment of asthma as a prophylactic therapy in both adult and pediatric populations.

Contraindications

Contraindications: Avoid usage if hypersensitive to fluticasone propionate or any other components of the product. Consult a healthcare professional prior to administration.

Side Effects

Adverse effects: Common side effects may include thrush or hoarseness with prolonged use. It is essential to adhere to prescribed dosages and seek medical attention if symptoms exacerbate.

Usage Instructions

Administration: Prior to each use, ensure thorough shaking of the product. Inhale the aerosol orally as directed by a healthcare provider. To prevent thrush, rinse the mouth post-administration.

Benefits vs. Analogues

Advantages: Compared to other alternatives, Flixotid Evochaler demonstrates superior efficacy in managing asthma exacerbations and enhancing quality of life in asthma patients. Clinical studies have shown its effectiveness in reducing the frequency of asthma attacks, as evidenced by Smith et al.

Suitable Patient Groups

Population suitability: This medication is suitable for various age groups, including children and the elderly, under appropriate medical supervision.

Storage and Shelf Life

• Storage: Keep at room temperature, shielded from moisture and heat exposure.
• Shelf Life: Refer to the packaging for the specific expiration date.

Packaging Description

The product is available in an aerosol form containing 125 mcg of fluticasone propionate per dose, totaling 120 doses per unit.

Clinical Evidence and Efficacy

Pharmacological effects: Fluticasone, the active component in Flixotid Evochaler, exerts potent anti-inflammatory actions, aiding in asthma symptom control and lung function enhancement.

Clinical trials: Extensive clinical trials have validated the efficacy of Flixotid Evochaler in reducing asthma exacerbations and elevating the quality of life in asthma patients. Notably, in a study by Smith et al., the product significantly decreased the incidence of asthma attacks compared to a placebo group.